Innovating Works

MC

Desconocido
CHIRALFORCE: Chiral separation of molecules enabled by enantioselective optical forces in integrated nanophotonic... SYMERES NETHERLANDS BV participó en un HORIZON EUROPE HORIZON-EIC-2021-PATHFINDEROPEN-01 Separating enantiomers is crucial to produce bio-active molecules, e.g., in early-phase drug discovery. CHIRALFORCE aims at a radically new...
2022-08-02 - 2026-05-31 | Financiado
BREAKthrough: Breaking the barrier - An integrated multidisciplinary approach to kill Gram-negative bacteria throu... SYMERES NETHERLANDS BV participó en un HORIZON EUROPE HORIZON-MSCA-2021-DN-01 Antimicrobial resistance, which is caused by multi-drug-resistant bacterial pathogens is a global health emergency. Gram-negative bacteria (...
2022-07-14 - 2026-12-31 | Financiado
BiocatCodeExpander: Genetic code expansion for biocatalysis and enzyme engineering doctoral network SYMERES NETHERLANDS BV participó en un HORIZON EUROPE HORIZON-MSCA-2021-DN-01 The expansion of the genetic code for the incorporation of non-canonical amino acids (NCAA) in proteins provides biotechnologists with an am...
2022-07-06 - 2026-12-31 | Financiado
ESCulab: European Screening Centre Unique Library for Attractive Biology SYMERES NETHERLANDS BV participó en un H2020 H2020-JTI-IMI2-2017-12-two-stage By bridging an important gap between basic research and drug development, ESCulab will facilitate the translation of fundamental scientific...
2018-12-18 - 2023-11-30 | Financiado
IT-DED3: Integrated Training in Dry Eye Disease Drug Development IT DED3 SYMERES NETHERLANDS BV participó en un H2020 H2020-MSCA-ITN-2017 The European network for Integrated Training in Dry Eye Disease Drug Development (IT-DED3) aims to deliver multidisciplinary and entrepreneu...
2017-08-17 - 2022-08-31 | Financiado
iDESIGN: Delivering Better Starting Points for Drug Discovery New Compound Libraries Driven By Intelligent D... SYMERES NETHERLANDS BV participó en un H2020 H2020-MSCA-ITN-2017 Whilst the need to generate new therapeutics has never been more important, drug discovery is at the same time becoming much more difficult....
2017-08-01 - 2021-12-31 | Financiado
EUC²LID: European Lead Factory SYMERES NETHERLANDS BV participó en un FP6 The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as...
2013-01-01 - 2018-05-31 | Financiado
EUC²LID: European Lead Factory SYMERES NETHERLANDS BV participó en un FP7 The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.